• About Us
    • Overview
    • Management Team
    • Board of Directors
  • Science
    • iNKTs
    • iNKT Platform
    • iNKT Combinations
  • Technology
  • Manufacturing
    • Our Process
    • Purity
  • Pipeline
  • Publications
  • Contact
    • Contact Us
    • Openings
  • Home
  • Chimeric Antigen Receptor

Chimeric Antigen Receptor - AgenTus Therapeutics

An immune cell weaponized with a synthetic receptor (CAR-T) which combines tumor specific targeting capability with T-cell activation to seek out and eradicate cancer.


References

  • CAR T-cell therapy: Full speed ahead.
    Sermer D, Brentjens R.
    Hematol Oncol.
    2019 Jun;37 Suppl 1:95-100. PMID: 311875332.

  • Switching on the green light for chimeric antigen receptor T-cell therapy.
    Mardiana S, Lai J, House IG, Beavis PA, Darcy PK.
    Clin Transl Immunology.
    2019 May 5;8(5):e1046. PMID: 31073403
    Free PMC Article

  • An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.
    Feins S, Kong W, Williams EF, Milone MC, Fraietta JA.
    Am J Hematol
    2019 May;94(S1):S3-S9. PMID: 30680780

  • Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR.
    J Immunother Cancer.
    2018 Dec 4;6(1):137. PMID: 30514386
    Free PMC Article

  • About Us
    • Management Team
    • Board of Directors
  • Science
    • iNKTs
    • iNKT Platform
    • iNKT Combinations
  • Technology
  • Manufacturing
    • Purity
  • Pipeline
  • Publications
  • Contact
    • Contact Us
    • Openings
Agentus

Terms and Conditions Privacy Policy Cookie Policy © Copyright 2021. All Rights Reserved.